Medindia LOGIN REGISTER
Medindia

Drug Safety Labeling Changes - February 2014

Food and Drug Administration (FDA) announces important safety label changes for prescription drugs almost every month. By implementing the label changes the FDA warns a physician of new side- effects, adverse reactions, contra-indications and precautions necessary for a drug. This information is important for safe practice of medicine.

Key to Label Sections

  • C - Contraindications
  • W - Warnings
  • P - Precautions
  • AR - Adverse Reactions
Drug Name Sections Modified
C W P AR
Acitretin - Capsules
Arformoterol Tartrate Inhalation - Solution
Tolvaptan - Tablets
Anagrelide - Capsules
Atomoxetine - Capsules
Azathioprine - Tablets and Injection
Boceprevir - 200 mg Capsules
Eltrombopag - Tablets
Esomeprazole - Delayed-Release Oral Suspension
Esomeprazole - for Intravenous Injection
Eszopiclone - Film Coated Oral Tablets
Everolimus - Tablets for Oral Administration
Everolimus - Tablets for Oral Suspension
Famotidine - Tablet
Golimumab - Injection For Intravenous Use
Ketoconazole - Tablet
Lovastatin
Menotropins - for Injection
Omeprazole - Delayed-Release Capsules
Omeprazole - Delayed-Release Oral Suspension
Palonosetron - Injection
Rivaroxaban - Tablets
Tacrolimus - Extended-Release Capsules
Urofollitropin - for Injection, Purified

2016 - Monthly Summary Report for Drug Label Changes

2015 - Monthly Summary Report for Drug Label Changes

2014 - Monthly Summary Report for Drug Label Changes

2013 - Monthly Summary Report for Drug Label Changes

2012 - Monthly Summary Report for Drug Label Changes

Drugs A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Ultimate Weight Loss Handbook: A Complete Guide to Achieving Your Goals
Stay Connected
Available on the Android Market Available on the App Store